ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

Parmar, Mkb; Torri, Valter; Bonaventura, Antonino; Bonazzi, Cristina; Colombo, Nicoletta; Jf, Delaloye; Marsoni, Silvia; Mangioni, C.; Sandercock, Josie; Sessa, C.; Williams, Chris; Tinazzi, Angelo; Flann, M.; Geiser, K; Scorpiglione, N.; Jf, Stewart; Chaves, Juliana Ramos; Palmeiro, E.B.; Curtain, Andrew; McCormack, Terry; Gennatas, C.; Marras, Francesco; Oppo, TG; Balestrino, Maurizio; Malzoni, Carmine; Malzoni, Mario; Belli, M; Geminiani, ML; Crestani, G; Monaco, Andrea Lo; Vavala,; Piatto, E; Barattini, G; Fornara, PG; Chetri, MC; Santeufemia, G; Artioli, Fabrizio; Carone, Davide; Fanizza, Giuseppe; Trentadue, R; Priolo, Domenico; Scollo, Paolo; Nigro, S Cavallaro; Petrina, M; Mastrantonio, P; Spanna, GD; R, Zagni; Belloni, C; Colleoni, Ramiro; Redaelli, L.; Cavagnini, A; Costanzo, Gianna Di; Perroni, D.; Arienti, Silvia; Orfanotti, G; Cantoni, FM; Secli, R; Bianchi, Antonio; Martinello, Rossella; Mollìca, G.; Maizzi, D; Picchiarelli, ME; Fiorini, Giulia; Borsani, M; Colombo, Emanuela; Garsia, S; Melgrati, Luigi; Paggi, G; Brunenghi, GM; Casini, Marco; Isa, L.; Algeri, R; Prozio, G; Belfiore, G; Angelini, Francesco; D’Aprile, Modesto; Moreschi, M; Mauri, ML; Natale, Nicola; Senzani, FM; Pavanato, G.; Poggi, Geraldina; Garuti, Giancarlo; Luerti, Massimo; Cruciani, Giorgio; Pagano, Francesco; Baccolo, M; Poddi, E R; Bocciolone, Luca; Sabelli, MA; Maggi, R; Restelli, C.; D'Antona, Adelaide; Locatelli, MC; Pessi, A.; Raina, Alberto; Chiari, Stefania; Gabriele, Annalisa; Pittelli,; P, Iacobelli; Dogliotti, Luigi; Gorzegno, G.; Musso, Pietro; Vegna, G; Coco, Gianluca Lo; Alletti, DG; Picciotto, Franco; Lucchese,; Epis, A.; Palumbo, VS di; Drudi, G.; Ravaioli, Alberto; Zampella, D; Morandi, MG; Gorga, Giovanna; Zucchelli, C; Cariello, S.; Galletto, L.; Sussio, M; Massacesi, Luca; Massacesi, M; Carli, Antonio Ferdinando; Tucci, Enrico; Tajani, E; Corrado, Giacomo; Bumma, S; Durando, Antonio; Massobrio, M; Sberveglieri, M; Biasio, Marzia De; Guercio, E; Jura, R; Danese, Saverio; Wierdis, T; Farnelli, C; Tarantino, G; Grassi, Roberto; Repetti, Fabrizio; Rocchi, Barbara; Grampa, M; Ercoli, Alfredo; Griso, C.; Signori, Emanuela; Zanini, Lucas Adalberto Geraldi; Presti, M.; Klimek, Małgorzata; Urbański, Krzysztof; Biswas, A.; Viegas, Osborne A.C.; Köchli, Ossi R.; Dreher, E.; Fey, Martin F.; Beck, Gavin; Ludin, Jacob A.; Bonnefoi, Hervé; Krauer, F.; Bauer, John J.; Delmore, Geoffrey; Furrer, C; Lorenz, Ute; Thürlimann, Beat; Bronz, Lucia; Sanna, P.; Wyss, Daniel F.; Goldhirsch, Aron; Gyr, Thomas; Leidi, L.; Pastorelli, Gianfranco; Pagani, Olivia; Rey, P; Hailer, U; Benz, JR; Kaye, SB; Reed, N.; Symonds, R.P.; Rj, Atkinson; Axford, AT; Rustin, G. J. S.; Seckl, MJ; Green, JA; Scott, Alexander P.; Guthrie, David; Harper, P.; Calman, F.; Dobbs, H.J.; Weir, P.; Cassoni, A; Lederman, JA; Souhami, R. L.; Bozzino, J; Adab, F.; Redman, Cwe; Scoble, J. E.; Paterson, M. E. L.; Daniel, F.; Cowley, Nicholas; Williams, Carmen J.; Spooner, D.; Hong, Anne; McIllmurray, M B; Hendy-Ibbs, P; Hall, '; Iveson, TJ; Whitehouse, J. M. A.; Garry, Ray; Lamont, Alan; Robinson, A.; Trask, C; Clubb, AW; Murrell, D. Shirley; Newman, Garry; Wilkins, M H; Goldthorp, WO; Roberts, JK; Radstone, D. J.; Whipp, MJ; Ledermann, JA; Pater, J; Buyse, Marc; Omura, George

doi:10.1016/s0140-6736(98)04119-1

Cited by 159 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No difference was found in survival between groups on the combination therapy regimen and those on carboplatin. Carboplatin, however, had fewer side effects and was advocated as the standard treatment for advanced ovarian cancer …”

Section: Resultsmentioning

confidence: 99%

“…Several bis[2,2‘:6‘,2‘ ‘-terpyridine-Pt(II)] complexes have been identified which are more effective than cisplatin against some human ovarian cell lines investigated and both cisplatin-resistant cell lines, indicating that a new class of platinum antitumor agents has been found which show little or no cross-resistance to cisplatin. These complexes are much more effective than carboplatin, the therapeutic agent currently advocated for the treatment of human ovarian cancers, and AMD473, which was recently selected for phase I clinical trials in the U.K …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cytotoxicity of 2,2‘:6‘,2‘ ‘-Terpyridineplatinum(II) Complexes against Human Ovarian Carcinoma

et al. 1999

View full text Add to dashboard Cite

2,2':6',2''-Terpyridineplatinum(II) complexes are shown to possess cytotoxicity against a number of human ovarian tumor cell lines. Many of the complexes show similar activity against cisplatin- and doxorubicin-resistant cell lines as the parental cells suggesting that there is little or no cross-resistance with cisplatin or doxorubicin. The cytotoxicity of bis[2,2':6',2''-terpyridineplatinum(II)] complexes is strongly dependent on the nature of the linker. Bis[2,2':6',2''-terpyridineplatinum(II)] complexes with a flexible linker at the 4'-position show poor cytotoxicity; by contrast bis[2,2':6',2''- terpyridineplatinum(II)] complexes with rigid and short linkers at platinum(II) are strikingly effective. Several of the compounds show greater cytotoxicity against human ovarian cell lines than carboplatin, the therapeutic agent currently advocated for the treatment of human ovarian cancers.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cytotoxicity of 2,2‘:6‘,2‘ ‘-Terpyridineplatinum(II) Complexes against Human Ovarian Carcinoma

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Besides surgery, adjuvant chemotherapy is a standard treatment option for ovarian cancer [161][162][163][164], including EAOC, particularly in advanced stages. Chemotherapeutic drugs commonly used in the treatment of ovarian cancer include platinum-based drugs like cisplatin and carboplatin, as well as taxanes such as paclitaxel [165][166][167][168][169]. However, the chemotherapy resistance of the ovarian clear-cell carcinoma subtype, also within EAOC, remains challenging and requires new therapeutic approaches.…”

Section: Chemotherapymentioning

confidence: 99%

Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance

Steinbuch,

Lüß,

Eltrop

et al. 2024

IJMS

View full text Add to dashboard Cite

Endometriosis is a chronic condition affecting reproductive-aged women, characterized by the growth of ectopic endometrial tissue. Despite being benign, endometriosis is associated with an increased risk of certain cancers, including endometriosis-associated ovarian cancer (EAOC). Ovarian cancer is rare, but more common in women with endometriosis, particularly endometrioid and clear-cell carcinomas. Factors such as hormonal imbalance, reproductive history, environmental exposures, and genetic predisposition contribute to the malignant transformation of endometriosis. Thus, understanding potential risk factors causing malignancy is crucial. Over the past few decades, various genetic mutations, microRNAs, as well as tumor microenvironmental factors have been identified, impacting pathways like PI3K/AKT/mTOR, DNA repair mechanisms, oxidative stress, and inflammation. Thus, this review aims to summarize molecular studies involved in EAOC pathogenesis as potential therapeutic targets. However, further research is needed to better understand the molecular and environmental factors driving EAOC development, to target the susceptibility of endometriotic lesions to malignant progression, and to identify effective therapeutic strategies.

show abstract

Current management of epithelial ovarian carcinoma: A review

Marsden

Friedlander

Hacker

2000

Semin. Surg. Oncol.

View full text Add to dashboard Cite

Epithelial carcinoma of the ovary is the most lethal of gynaecological malignancies and it affects about one in 70 women in developed countries. Over 75% of women with the disease have tumour spread beyond the pelvis at the time of diagnosis, and their treatment requires the appropriate use of surgery and chemotherapy. The strategies used in the treatment of ovarian cancer are constantly evolving. An overview of current treatment regimens and their evolution is provided, with particular emphasis on the interdependence of surgery and chemotherapy in the optimal management of the disease. Semin. Surg. Oncol. 19:11–19, 2000. © 2000 Wiley‐Liss, Inc.

show abstract

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

Cited by 159 publications

References 10 publications

Cytotoxicity of 2,2‘:6‘,2‘ ‘-Terpyridineplatinum(II) Complexes against Human Ovarian Carcinoma

Cytotoxicity of 2,2‘:6‘,2‘ ‘-Terpyridineplatinum(II) Complexes against Human Ovarian Carcinoma

Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance

Current management of epithelial ovarian carcinoma: A review

Contact Info

Product

Resources

About